A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica
Delveinsight
DECEMBER 29, 2020
Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Billion Myovant/ Pfizer Deal. Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.
52 
Let's personalize your content